Cargando…

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV

Detalles Bibliográficos
Autores principales:	Strati, Paolo, Pasvolsky, Oren, Feng, Lei, Xu, Guofan, Tewari, Sanjit O., Varghese, Jaimole, Ow, Karla, Santiago, Minifrida, Al Zaki, Ajlan, Jallouk, Andrew, Neelapu, Sattva S., Kebriaei, Partow, Shpall, Elizabeth J., Ahmed, Sairah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250904/ https://www.ncbi.nlm.nih.gov/pubmed/36745104 http://dx.doi.org/10.1182/bloodadvances.2022009622

Ejemplares similares

Day 30 SUV(max) predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy
por: Al Zaki, Ajlan, et al.
Publicado: (2022)

Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
por: Jallouk, Andrew P., et al.
Publicado: (2022)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2023)

Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas
por: Revailler, Wendy, et al.
Publicado: (2022)

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2020)

Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant
por: Nieto, Yago, et al.
Publicado: (2023)

COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients with Current or Prior Breast Cancer and Other Malignancies: Cross-Sectional Imaging Findings on MRI, CT, and PET-CT
por: Lane, Deanna L, et al.
Publicado: (2021)

Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
por: Greenbaum, Uri, et al.
Publicado: (2020)

P1081: A MULTICENTER OBSERVATIONAL STUDY ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR LARGE B-CELL (LBCL) AND MANTLE CELL (MCL) LYMPHOMAS: THE ITALIAN CART-SIE REAL LIFE EXPERIENCE
por: Chiappella, Annalisa, et al.
Publicado: (2023)

Functional and Kinetic Comparison of Alanine Cysteine Serine Transporters ASCT1 and ASCT2
por: Wang, Jiali, et al.
Publicado: (2022)

Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future
por: Sanchez-Petitto, Gabriela, et al.
Publicado: (2023)

Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2021)

P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)
por: Munoz, Javier, et al.
Publicado: (2023)

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2021)

A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma
por: Fahrmann, Johannes F., et al.
Publicado: (2022)

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
por: Abramson, Jeremy S., et al.
Publicado: (2022)

Mesenchymal Stem Cell Therapy in the Treatment of Acute and Chronic Graft Versus Host Disease
por: Kebriaei, Partow, et al.
Publicado: (2011)

Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1(+) T-cell subsets
por: Chu, Fuliang, et al.
Publicado: (2014)

CXCR5+CD8+ T cells are localized in B cell follicles and germinal centers and exhibit regulatory and anti-tumor function
por: Chu, Fuliang, et al.
Publicado: (2015)

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
por: Gunther, Jillian R., et al.
Publicado: (2020)

Therapy of newly diagnosed follicular lymphoma
por: Westin, Jason R., et al.
Publicado: (2012)

P1197: AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY
por: Strati, P., et al.
Publicado: (2022)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
por: Fang, Penny Q., et al.
Publicado: (2021)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine‐addicted OSCC cells
por: Luo, Yijun, et al.
Publicado: (2020)

Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL
por: Perez, Ariel, et al.
Publicado: (2022)

Characterization of the Two CART Genes (CART1 and CART2) in Chickens (Gallus gallus)
por: Cai, Guoqing, et al.
Publicado: (2015)

ASCT2 is the primary serine transporter in cancer cells
por: Conger, Kelly O., et al.
Publicado: (2023)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

P1299: OUTCOMES OF YOUNG ADULTS (AGED ≤40 YEARS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANT
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Therapeutic Vaccine for Lymphoma
por: Lee, Seung-Tae, et al.
Publicado: (2007)

GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma
por: Sun, Hong-Wei, et al.
Publicado: (2016)

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
por: Huls, M. Helen, et al.
Publicado: (2013)

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience
por: Trando, Aaron, et al.
Publicado: (2023)

Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type
por: Mehta, Rohtesh S., et al.
Publicado: (2023)

PD-L1(+) macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2023)

Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jsfutl1dm7eacitj2pd5o5mb5f